QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
NASDAQ:TBPH

Theravance Biopharma - TBPH Stock Forecast, Price & News

$10.65
-0.05 (-0.47%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.62
$10.84
50-Day Range
$10.40
$11.44
52-Week Range
$7.53
$11.83
Volume
307,589 shs
Average Volume
444,945 shs
Market Capitalization
$717.49 million
P/E Ratio
0.95
Dividend Yield
N/A
Price Target
$14.67

Theravance Biopharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
37.7% Upside
$14.67 Price Target
Short Interest
Bearish
14.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Theravance Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$581,861 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

869th out of 1,029 stocks

Pharmaceutical Preparations Industry

428th out of 501 stocks

TBPH stock logo

About Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
SVB Securities Reaffirms Their Buy Rating on Theravance Biopharma (TBPH)
Company News for Sep 20, 2022
Theravance Biopharma Rises 6% On News Of Share Buyback
Theravance To Buy Back $250 Mln Of Shares
See More Headlines
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Company Calendar

Last Earnings
11/07/2022
Today
2/03/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
Fax
N/A
Employees
359
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.67
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+37.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-199,430,000.00
Net Margins
1,646.84%
Pretax Margin
-118.56%

Debt

Sales & Book Value

Annual Sales
$55.31 million
Book Value
($4.59) per share

Miscellaneous

Free Float
64,132,000
Market Cap
$717.49 million
Optionable
Optionable
Beta
0.51

Key Executives

  • Rick E. Winningham
    Chairman & Chief Executive Officer
  • Andrew Asa Hindman
    Chief Financial Officer & Senior Vice President
  • Vijay Sabesan
    Senior Vice President-Technical Operations
  • Philip D. Worboys
    Senior VP-Research & Translational Science
  • Bradford J. Shafer
    Secretary, Executive VP & General Counsel













TBPH Stock - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.
View TBPH analyst ratings
or view top-rated stocks.

What is Theravance Biopharma's stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month target prices for Theravance Biopharma's stock. Their TBPH share price forecasts range from $11.00 to $19.00. On average, they expect the company's stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for TBPH
or view top-rated stocks among Wall Street analysts.

How have TBPH shares performed in 2023?

Theravance Biopharma's stock was trading at $11.22 at the beginning of 2023. Since then, TBPH stock has decreased by 4.5% and is now trading at $10.72.
View the best growth stocks for 2023 here
.

When is Theravance Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our TBPH earnings forecast
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Monday, November, 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. The biopharmaceutical company had revenue of $12.45 million for the quarter, compared to analysts' expectations of $19.09 million.

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Palliser Capital UK Ltd (0.14%), Strs Ohio (0.02%), SG Americas Securities LLC (0.02%), Allspring Global Investments Holdings LLC (0.02%), Gladius Capital Management LP (0.01%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Rick E Winningham.
View institutional ownership trends
.

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $10.72.

How much money does Theravance Biopharma make?

Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $722.21 million and generates $55.31 million in revenue each year. The biopharmaceutical company earns $-199,430,000.00 in net income (profit) each year or $11.26 on an earnings per share basis.

How many employees does Theravance Biopharma have?

The company employs 359 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.

This page (NASDAQ:TBPH) was last updated on 2/3/2023 by MarketBeat.com Staff